Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system

Lemarié, F., Croft, D.R., Tate, R.J., Ryan, K.M. and Dufès, C. (2012) Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system. Biomaterials, 33(9), pp. 2701-2709. (doi:10.1016/j.biomaterials.2011.12.019)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1016/j.biomaterials.2011.12.019

Abstract

The potential of gene therapy to treat cancer is hampered by the lack of safe and efficacious gene delivery systems able to selectively deliver therapeutic genes to tumors by intravenous administration. With the long-term aim of developing an efficacious cancer-targeted gene medicine, we demonstrated that transferrin-bearing polypropylenimine dendrimer complexed to a plasmid DNA encoding p73 led to an enhanced anti-proliferative activity in vitro, by up to 120-fold in A431 compared to the unmodified dendriplex. In vivo, the intravenous administration of this p73-encoding dendriplex resulted in a rapid and sustained inhibition of tumor growth over one month, with complete tumor suppression for 10% of A431 and B16-F10 tumors and long-term survival of the animals. The treatment was well tolerated by the animals, with no apparent signs of toxicity. These results suggest that the p73-encoding tumor-targeted polypropylenimine dendrimer should be further explored as a therapeutic strategy for cancer therapy.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Croft, Dr Daniel and Ryan, Professor Kevin
Authors: Lemarié, F., Croft, D.R., Tate, R.J., Ryan, K.M., and Dufès, C.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Biomaterials
ISSN:0142-9612
ISSN (Online):1878-5905
Published Online:24 December 2011

University Staff: Request a correction | Enlighten Editors: Update this record